Seeking Alpha
20 Nov 2026, 18:43 UTC · 2h ago
Biogen: Why I'm Still Bullish Despite Market Turmoil
Impact · against what's priced in
The reported efficacy data for Leqembi provides a fundamental catalyst for BIIB, as the market currently discounts the drug's full commercial potential. While EPS guidance and quarterly sales growth are largely consistent with current expectations, the relative risk reduction data supports the bull case for expanded adoption.
- BIIB+0.40
Challenges what's priced in
- The price assumes
the full upside of LEQEMBI's subcutaneous autoinjector
The data showing Leqembi reduced the relative risk of disease progression by 49% versus ADNI strengthens the clinical case for the drug, supporting the valuation upside that the market currently declines to pay for regarding expanded population access.
What BIIB's price assumes · Sep 10





